VolitionRX Ltd (NYSEAMERICAN:VNRX) was the target of a large growth in short interest in December. As of December 31st, there was short interest totalling 327,999 shares, a growth of 80.3% from the December 14th total of 181,885 shares. Based on an average daily volume of 113,840 shares, the short-interest ratio is presently 2.9 days. Approximately 1.5% of the company’s stock are short sold.
Shares of NYSEAMERICAN VNRX opened at $2.33 on Friday. VolitionRX has a 1 year low of $1.44 and a 1 year high of $4.00.
VolitionRX (NYSEAMERICAN:VNRX) last announced its quarterly earnings results on Wednesday, November 7th. The medical research company reported ($0.14) EPS for the quarter, hitting analysts’ consensus estimates of ($0.14).
Separately, Oppenheimer set a $5.00 target price on shares of VolitionRX and gave the stock a “buy” rating in a research note on Friday, November 9th.
TRADEMARK VIOLATION NOTICE: This news story was originally published by Ticker Report and is the property of of Ticker Report. If you are reading this news story on another domain, it was stolen and republished in violation of US & international trademark and copyright laws. The correct version of this news story can be accessed at https://www.tickerreport.com/banking-finance/4071653/short-interest-in-volitionrx-ltd-vnrx-rises-by-80-3.html.
VolitionRX Company Profile
VolitionRX Limited, a life sciences company, engages in the development of blood tests to help diagnose a range of cancers worldwide. The company develops 39 epigenetic Nu.Q blood assays based on its Nucleosomics biomarker discovery platform. VolitionRX Limited is based in Singapore.
Featured Article: Short Selling – Explanation For Shorting Stocks
Receive News & Ratings for VolitionRX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VolitionRX and related companies with MarketBeat.com's FREE daily email newsletter.